• Joanna Tieu, Jonathan Tl Cheah, Rachel J Black, Robin Christensen, Nilasha Ghosh, Pamela Richards, Joanna Robson, Beverley Shea, Lee S Simon, Jasvinder A Singhi, Peter Tugwell, Maarten Boers, Marco A Alba Garibay, Corrado Campochiaro, Simon Decary, Maarten de Witt, Anthony P Fernandez, Helen I Keen, Lauren King, Andrea Hinojosa-Azaola, Cathie Hofstetter, Inna Gaydukova, Michael D George, Latika Gupta, Suellen Lyne, Ashima Makol, Chetan Mukhtyar, Win Min Oo, Michelle Petri, Huai Leng Pisaniello, Sebastian E Sattui, Oscar Russell, Vitor Teixeira, Karine Toupin-April, Courage Uhunmwangho, Margaret Whitstock, Kevin Yip, Sarah L Mackie, Susan M Goodman, and Catherine L Hill.
• Rheumatology Research Group, Basil Hetzel Institute, Adelaide, Australia, Adelaide Medical School, University of Adelaide, Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, Rheumatology Unit, Lyell McEwin Hospital, Adelaide, Australia, Adelaide, Australia.
• Semin. Arthritis Rheum. 2021 Oct 1; 51 (5): 1139-1145.

ObjectiveOur primary objective was to develop an Outcome Measures in Rheumatology (OMERACT) core domain set to capture the impact of glucocorticoids (GC), both positive and negative, on patients with Rheumatic conditions.MethodsThe OMERACT Filter 2.1 was used to guide core domain selection. Systematic literature reviews, qualitative studies and quantitative surveys were conducted by the OMERACT GC Impact working group to identify candidate domains for a core domain set. A summary of prior work and Delphi exercise were presented at the OMERACT 2020 virtual GC workshop. A proposed GC Impact core domain set derived from this work was presented for discussion in facilitated breakout groups. Participants voted on the proposed GC Impact core domain set.Results113 people, including 23 patient research partners, participated in two virtual workshops conducted at different times on the same day. The proposed mandatory domains to be evaluated in clinical trials involving GCs were: infection, bone fragility, hypertension, diabetes, weight, fatigue, mood disturbance and death. In addition, collection of disease specific outcomes was included in the core domain set as "mandatory in specific circumstances". The proposed core domain set was endorsed by 100% (23/23) of the patient research partners and 92% (83/90) of the remaining participants, including clinicians, researchers and industry stakeholders.ConclusionA GC Impact core domain set was endorsed at the OMERACT 2020 virtual workshop. The OMERACT GC Impact working group will now progress to identify, develop and validate measurement tools to best address these domains in clinical trials.Copyright © 2021. Published by Elsevier Inc.

5 keywords...

hide…